{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Abpro Holdings, Inc"},"Symbol":{"label":"Symbol","value":"ABP"},"Address":{"label":"Address","value":"68 CUMMINGS,PARK DRIVE, WOBURN, Massachusetts, 01801, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Abpro Corporation, a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers, and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as IE LAB Inc. and changed its name to Abpro Corporation in October 2007. Abpro Corporation was incorporated in 2004 and is headquartered in Woburn, Massachusetts."},"CompanyUrl":{"label":"Company Url","value":"https://www.atlanticcoastalacquisition.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Yan Pui Chan","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}